Daxor Co. (NASDAQ:DXR) Sees Large Increase in Short Interest

Daxor Co. (NASDAQ:DXR) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 9,000 shares, a growth of 7.1% from the December 31st total of 8,400 shares. Based on an average daily volume of 16,800 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the company’s shares are short sold.

Daxor Trading Up 0.4 %

Shares of NASDAQ:DXR traded up $0.03 during trading on Tuesday, reaching $7.81. The stock had a trading volume of 577 shares, compared to its average volume of 5,255. Daxor has a 52 week low of $7.19 and a 52 week high of $10.00. The firm’s fifty day moving average is $8.33 and its 200 day moving average is $8.73.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC raised its stake in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent SEC filing. 1.34% of the stock is currently owned by institutional investors.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.